Zacks Research Has Positive Estimate for IRWD Q1 Earnings

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Equities research analysts at Zacks Research increased their Q1 2026 earnings estimates for Ironwood Pharmaceuticals in a note issued to investors on Tuesday, January 20th. Zacks Research analyst Team now anticipates that the biotechnology company will post earnings per share of $0.07 for the quarter, up from their previous forecast of $0.01. Zacks Research has a “Strong-Buy” rating on the stock. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.10 per share. Zacks Research also issued estimates for Ironwood Pharmaceuticals’ Q2 2026 earnings at $0.27 EPS, Q3 2026 earnings at $0.40 EPS, FY2026 earnings at $0.98 EPS, Q2 2027 earnings at $0.02 EPS and Q4 2027 earnings at ($0.02) EPS.

A number of other brokerages have also recently commented on IRWD. Craig Hallum upgraded Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, January 5th. Citigroup upgraded Ironwood Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Monday, January 5th. Wells Fargo & Company lifted their price objective on shares of Ironwood Pharmaceuticals from $3.00 to $5.00 and gave the stock an “equal weight” rating in a research note on Monday, January 5th. Citizens Jmp upgraded shares of Ironwood Pharmaceuticals from a “market perform” rating to a “market outperform” rating and set a $8.00 price objective on the stock in a research report on Monday, January 5th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Ironwood Pharmaceuticals in a report on Monday, December 29th. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Ironwood Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $5.74.

Ironwood Pharmaceuticals Price Performance

Shares of NASDAQ IRWD opened at $5.23 on Thursday. Ironwood Pharmaceuticals has a 1-year low of $0.53 and a 1-year high of $5.78. The business’s 50 day moving average is $3.77 and its two-hundred day moving average is $2.18. The stock has a market capitalization of $850.82 million, a P/E ratio of 32.69 and a beta of 0.18.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its earnings results on Monday, November 10th. The biotechnology company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.15. Ironwood Pharmaceuticals had a net margin of 8.70% and a negative return on equity of 15.17%. The firm had revenue of $122.06 million for the quarter, compared to analysts’ expectations of $74.22 million.

Institutional Trading of Ironwood Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Integrated Wealth Concepts LLC boosted its stake in shares of Ironwood Pharmaceuticals by 21.4% during the third quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 3,406 shares during the period. Vise Technologies Inc. bought a new stake in Ironwood Pharmaceuticals during the 3rd quarter valued at about $39,000. BNP Paribas Financial Markets boosted its position in Ironwood Pharmaceuticals by 83.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 34,331 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 15,594 shares during the period. OVERSEA CHINESE BANKING Corp Ltd purchased a new stake in Ironwood Pharmaceuticals in the 2nd quarter valued at about $25,000. Finally, SG Americas Securities LLC bought a new position in Ironwood Pharmaceuticals in the 3rd quarter worth about $48,000.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.